Use of evidence-based meds increasing for STEMI, NSTEMI

Use of evidence-based meds increasing for STEMI, NSTEMI
Evidence-based therapies are increasingly being used to treat patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction, according to research published in the Feb. 1 issue of The American Journal of Cardiology.

(HealthDay)—Evidence-based therapies are increasingly being used to treat patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), according to research published in the Feb. 1 issue of The American Journal of Cardiology.

Emily C. O'Brien, Ph.D., M.S.P.H., of the University of North Carolina at Chapel Hill, and colleagues used data from the Atherosclerosis Risk in Communities Community Surveillance Study to examine trends from 1987 to 2008 in the use of 10 medical therapies and procedures for STEMI and NSTEMI for 30,986 cases of definite or probable .

The researchers found that, for both STEMI and NSTEMI, increases were noted in the use of angiotensin-converting enzyme inhibitors (6.4 and 5.5 percent, respectively); antiplatelet therapy other than aspirin (5.0 and 3.7 percent); lipid-lowering drugs (4.5 and 3.0 percent); and beta-blockers (2.7 and 4.2 percent). Smaller increases were noted in the use of aspirin (1.2 and 1.9 percent) and heparin (0.8 and 1.7 percent). For patients with STEMI, use of thrombolytic agents and the number of procedures decreased.

"This is the first study to present long-term trends in in-hospital treatment for patients with STEMIs and those with NSTEMIs using validated clinical data," the authors write. "We observed an increase in the use of six of seven medications over the study period in patients with STEMIs and those with NSTEMIs."

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Some heart attack rates declining and survival improving

date Jan 12, 2011

Coronary syndromes vary in severity, ranging from unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), to ST-segment elevation myocardial infarction (STEMI), the most severe diagnosis. Little data exist ...

Multiple factors motivate no reperfusion in STEMI

date Aug 02, 2012

(HealthDay) -- For patients presenting with ST-segment elevation myocardial infarction (STEMI), the decision for no reperfusion is usually multifactorial, with the most common factor being advanced age, according ...

Recommended for you

Catheterization increasing for seniors with STEMI

date 14 hours ago

(HealthDay)—From 1999 to 2009 there was a decrease in the proportion of older adults with ST-segment elevation acute myocardial infarction (STEMI) who did not undergo cardiac catheterization, according ...

Race influences warfarin dose, study says

date 22 hours ago

A new report demonstrates that clinical and genetic factors affecting dose requirements for warfarin vary by race. The study, published online today in Blood, the Journal of the American Society of Hematology (ASH), propose ...

Even moderate BMI reduction could ease A-fib burden

date May 29, 2015

(HealthDay)—Incremental increases in body mass index (BMI) are associated with excess risk of incident, postoperative, and post-ablation atrial fibrillation (AF), according to a review published online ...

Personalized saline may provide solution to heart death

date May 29, 2015

Saline solution is a staple of every hospital. No matter the ailment, doctors have known for more than a century that saline is key to keeping patients hydrated and maintaining their blood pressure levels. ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.